OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
🇺🇸United States
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2020-04-17
- Target Recruit Count
- 3
- Registration Number
- NCT02020278
Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2018-09-26
- Target Recruit Count
- 9
- Registration Number
- NCT02012959
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2016-03-29
- Target Recruit Count
- 37
- Registration Number
- NCT02013531
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2016-03-29
- Target Recruit Count
- 48
- Registration Number
- NCT02013609
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2016-03-29
- Target Recruit Count
- 49
- Registration Number
- NCT02013622
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2015-12-29
- Target Recruit Count
- 61
- Registration Number
- NCT02012218
- Locations
- 🇺🇸
Goldpoint Clinical Research, Indianapolis, Indiana, United States
🇺🇸St. Louis Clinical Trials, St. Louis, Missouri, United States
🇺🇸Behavioral Medical Research of Staten Island, Staten Island, New York, United States
A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2016-05-16
- Target Recruit Count
- 30
- Registration Number
- NCT02009878
- Locations
- 🇪🇸
Hospital Universitario Clinico San Carlos, Madrid, Spain
🇩🇪Medizinische Klinik im Klinikum Hannover, Hannover, Niedersachsen, Germany
🇨🇿Vseobecna fakultni nemocnice V Praze, Praha, Czech Republic
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 48
- Registration Number
- NCT01994473
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸Collaborative Neuroscience Network, LLC, Long Beach, California, United States
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
Phase 2
Withdrawn
- Conditions
- Interventions
Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 105
- Registration Number
- NCT01972711
- Locations
- 🇬🇧
University of Manchester, Neuroscience and Psychiatry Unit, Manchester, United Kingdom
🇬🇧Department of Psychiatry, University of Oxford, Warneford Hospital, Headington, Oxford, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath